by Robin M. Sundstrom •
May 13, 2014 •
Business Focus, Capital markets/Funding, Feature, Feature Slider, Featured-Slides-Home, In Depth, Opinions •
Comments (0) •
To the joy of biotech CEOs everywhere, the NASDAQ Biotech Index rose more than 50 percent through 2013, indicating the continuation of a powerful surge of interest after years of what can most politely be described as lacklustre performance.
Comments are closed.
© 2017 Biotechnology Focus™
Powered by Wordpress. Designed by Themnific™